VANDA PHARMACEUTICALS INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
VANDA PHARMACEUTICALS INC. (VNDA) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $11.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-06
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $10.20M, a 9.94% decline year-over-year.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $1.48M, a 73.74% decline year-over-year.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $9.08M.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$10.22M.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $15.82M, a 826.23% increase from fiscal 2024.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $1.71M.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$10.98M, a 193.14% decline from fiscal 2022.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $11.79M, a 287.93% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $10.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $11.68M 10-Q · filed 2026-08-06 | $20.76M derived: sum of 3 quarters · filed 2026-08-06 | $10.54M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $1.48M 10-Q · filed 2026-05-07 | $10.56M derived: sum of 2 quarters · filed 2026-05-07 | $334.00K derived: sum of 3 quarters · filed 2026-05-07 | $11.66M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $9.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$1.15M derived: sum of 2 quarters · filed 2026-02-12 | $10.18M derived: sum of 3 quarters · filed 2026-08-06 | $15.82M 10-K · filed 2026-02-12 | |||
| 2025-09-30 | -$10.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.11M derived: sum of 2 quarters · filed 2026-08-06 | $6.74M 10-Q · filed 2025-10-30 | $4.62M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $11.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $16.97M 10-Q · filed 2026-08-06 | $14.84M derived: sum of 3 quarters · filed 2026-08-06 | $14.37M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $5.64M 10-Q · filed 2026-05-07 | $3.51M derived: sum of 2 quarters · filed 2026-05-07 | $3.04M derived: sum of 3 quarters · filed 2026-05-07 | $6.18M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | -$2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$2.60M derived: sum of 2 quarters · filed 2026-02-12 | $543.00K derived: sum of 3 quarters · filed 2026-02-12 | $1.71M 10-K · filed 2026-02-12 | |||
| 2024-09-30 | -$469.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $2.67M derived: sum of 2 quarters · filed 2025-10-30 | $3.83M 10-Q · filed 2025-10-30 | $7.17M derived: sum of 4 quarters · filed 2026-02-12 | |||
| 2024-06-30 | $3.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $4.30M 10-Q · filed 2025-07-31 | $7.63M derived: sum of 3 quarters · filed 2026-02-12 | $7.36M derived: sum of 4 quarters · filed 2026-02-12 | |||
| 2024-03-31 | $1.17M 10-Q · filed 2025-05-08 | $4.50M derived: sum of 2 quarters · filed 2026-02-12 | $4.22M derived: sum of 3 quarters · filed 2026-02-12 | $972.00K derived: sum of 4 quarters · filed 2026-02-12 | |||
| 2023-12-31 | $3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $3.05M derived: sum of 2 quarters · filed 2026-02-12 | -$193.00K derived: sum of 3 quarters · filed 2026-02-12 | -$10.98M 10-K · filed 2026-02-12 | |||
| 2023-09-30 | -$280.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$3.52M derived: sum of 2 quarters · filed 2024-11-07 | -$14.31M 10-Q · filed 2024-11-07 | -$17.59M derived: sum of 4 quarters · filed 2025-02-14 | |||
| 2023-06-30 | -$3.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$14.04M 10-Q · filed 2024-08-01 | -$17.31M derived: sum of 3 quarters · filed 2025-02-14 | -$15.97M derived: sum of 4 quarters · filed 2025-02-14 | |||
| 2023-03-31 | -$10.79M 10-Q · filed 2024-05-09 | -$14.07M derived: sum of 2 quarters · filed 2025-02-14 | -$12.73M derived: sum of 3 quarters · filed 2025-02-14 | -$12.42M derived: sum of 4 quarters · filed 2025-02-14 | |||
| 2022-12-31 | -$3.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | -$1.94M derived: sum of 2 quarters · filed 2025-02-14 | -$1.63M derived: sum of 3 quarters · filed 2025-02-14 | $11.79M 10-K · filed 2025-02-14 | |||
| 2022-09-30 | $1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.64M derived: sum of 2 quarters · filed 2023-11-09 | $15.07M 10-Q · filed 2023-11-09 | $17.25M derived: sum of 4 quarters · filed 2024-02-08 | |||
| 2022-06-30 | $306.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-28 | $13.73M 10-Q · filed 2023-07-28 | $15.91M derived: sum of 3 quarters · filed 2024-02-08 | $15.88M derived: sum of 4 quarters · filed 2024-02-08 | |||
| 2022-03-31 | $13.43M 10-Q · filed 2023-05-03 | $15.61M derived: sum of 2 quarters · filed 2024-02-08 | $15.58M derived: sum of 3 quarters · filed 2024-02-08 | $21.74M derived: sum of 4 quarters · filed 2024-02-08 | |||
| 2021-12-31 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-08 | $2.15M derived: sum of 2 quarters · filed 2024-02-08 | $8.31M derived: sum of 3 quarters · filed 2024-02-08 | $3.04M 10-K · filed 2024-02-08 | |||
| 2021-09-30 | -$28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $6.13M derived: sum of 2 quarters · filed 2022-11-03 | $860.00K 10-Q · filed 2022-11-03 | $3.21M derived: sum of 4 quarters · filed 2023-02-09 | |||
| 2021-06-30 | $6.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $888.00K 10-Q · filed 2022-08-04 | $3.24M derived: sum of 3 quarters · filed 2023-02-09 | $3.76M derived: sum of 4 quarters · filed 2023-02-09 | |||
| 2021-03-31 | -$5.27M 10-Q · filed 2022-05-06 | -$2.92M derived: sum of 2 quarters · filed 2023-02-09 | -$2.40M derived: sum of 3 quarters · filed 2023-02-09 | $282.00K derived: sum of 4 quarters · filed 2023-02-09 | |||
| 2020-12-31 | $2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $2.88M derived: sum of 2 quarters · filed 2023-02-09 | $5.55M derived: sum of 3 quarters · filed 2023-02-09 | $3.76M 10-K · filed 2023-02-09 | |||
| 2020-09-30 | $525.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $3.20M derived: sum of 2 quarters · filed 2021-11-04 | $1.41M 10-Q · filed 2021-11-04 | $1.73M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2020-06-30 | $2.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $883.00K 10-Q · filed 2021-07-29 | $1.20M derived: sum of 3 quarters · filed 2022-02-24 | -$768.00K derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2020-03-31 | -$1.79M 10-Q · filed 2021-05-06 | -$1.48M derived: sum of 2 quarters · filed 2022-02-24 | -$3.45M derived: sum of 3 quarters · filed 2022-02-24 | -$1.79M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2019-12-31 | $317.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$1.65M derived: sum of 2 quarters · filed 2022-02-24 | $1.00K derived: sum of 3 quarters · filed 2022-02-24 | $3.51M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | -$1.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | -$316.00K derived: sum of 2 quarters · filed 2020-10-29 | $3.19M 10-Q · filed 2020-10-29 | $5.75M derived: sum of 4 quarters · filed 2021-02-11 | |||
| 2019-06-30 | $1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $5.16M 10-Q · filed 2020-08-06 | $7.72M derived: sum of 3 quarters · filed 2021-02-11 | $6.11M derived: sum of 4 quarters · filed 2021-02-11 | |||
| 2019-03-31 | $3.51M 10-Q · filed 2020-05-07 | $6.07M derived: sum of 2 quarters · filed 2021-02-11 | $4.46M derived: sum of 3 quarters · filed 2021-02-11 | $5.62M derived: sum of 4 quarters · filed 2021-02-11 | |||
| 2018-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $950.00K derived: sum of 2 quarters · filed 2021-02-11 | $2.11M derived: sum of 3 quarters · filed 2021-02-11 | -$618.00K 10-K · filed 2021-02-11 | |||
| 2018-09-30 | -$1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$451.00K derived: sum of 2 quarters · filed 2019-11-07 | -$3.18M 10-Q · filed 2019-11-07 | -$1.78M derived: sum of 4 quarters · filed 2020-02-26 | |||
| 2018-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$1.57M 10-Q · filed 2019-08-01 | -$167.00K derived: sum of 3 quarters · filed 2020-02-26 | $1.74M derived: sum of 4 quarters · filed 2020-02-26 | |||
| 2018-03-31 | -$2.73M 10-Q · filed 2019-05-03 | -$1.33M derived: sum of 2 quarters · filed 2020-02-26 | $576.00K derived: sum of 3 quarters · filed 2020-02-26 | $1.78M derived: sum of 4 quarters · filed 2020-02-26 | |||
| 2017-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $3.31M derived: sum of 2 quarters · filed 2020-02-26 | $4.51M derived: sum of 3 quarters · filed 2020-02-26 | $5.95M 10-K · filed 2020-02-26 | |||
| 2017-09-30 | $1.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $3.11M derived: sum of 2 quarters · filed 2018-11-07 | $4.55M 10-Q · filed 2018-11-07 | $2.55M 10-Q · filed 2017-11-08 | $3.40M derived: sum of 4 quarters · filed 2019-02-19 | ||
| 2017-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $2.65M 10-Q · filed 2018-08-02 | $1.49M derived: sum of 3 quarters · filed 2019-02-19 | $840.00K derived: sum of 4 quarters · filed 2019-02-19 | |||
| 2017-03-31 | $1.44M 10-Q · filed 2018-05-02 | $287.00K derived: sum of 2 quarters · filed 2019-02-19 | -$364.00K derived: sum of 3 quarters · filed 2019-02-19 | -$4.94M derived: sum of 4 quarters · filed 2019-02-19 | |||
| 2016-12-31 | -$1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | -$1.81M derived: sum of 2 quarters · filed 2019-02-19 | -$6.38M derived: sum of 3 quarters · filed 2019-02-19 | $575.00K 10-K · filed 2019-02-19 | |||
| 2016-09-30 | -$651.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$5.22M derived: sum of 2 quarters · filed 2017-11-08 | $1.73M 10-Q · filed 2017-11-08 | $3.42M derived: sum of 4 quarters · filed 2017-11-08 | |||
| 2016-06-30 | -$4.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $2.38M 10-Q · filed 2017-08-03 | $2.22M 10-Q · filed 2016-07-28 | $4.08M derived: sum of 3 quarters · filed 2017-08-03 | $3.07M derived: sum of 4 quarters · filed 2017-08-03 | ||
| 2016-03-31 | $6.96M 10-Q · filed 2017-05-03 | $6.88M 10-Q · filed 2016-05-05 | $8.65M derived: sum of 2 quarters · filed 2017-05-03 | $7.64M derived: sum of 3 quarters · filed 2017-05-03 | $5.53M derived: sum of 4 quarters · filed 2017-05-03 | ||
| 2015-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $686.00K derived: sum of 2 quarters · filed 2017-02-17 | -$1.42M derived: sum of 3 quarters · filed 2017-02-17 | $9.43M 10-K · filed 2017-02-17 | |||
| 2015-09-30 | -$1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$3.12M derived: sum of 2 quarters · filed 2016-11-03 | $7.74M 10-Q · filed 2016-11-03 | $38.39M 10-Q · filed 2015-11-04 | $6.90M derived: sum of 4 quarters · filed 2017-02-17 | ||
| 2015-06-30 | -$2.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $8.75M 10-Q · filed 2016-07-28 | $7.91M derived: sum of 3 quarters · filed 2017-02-17 | ||||
| 2015-03-31 | $10.85M 10-Q · filed 2016-05-05 | $10.01M derived: sum of 2 quarters · filed 2017-02-17 | |||||
| 2014-12-31 | -$839.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $1.03M 10-K · filed 2017-02-17 | |||||
| 2014-09-30 | $1.87M 10-Q · filed 2015-11-04 | ||||||
| 2013-12-31 | $261.00K 10-K · filed 2016-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |